StockVS

NASDAQ · Biotechnology · USD

Curanex Pharmaceuticals Inc (CURX) Stock Analysis

Curanex Pharmaceuticals Inc (CURX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CURX

$5.05

+$0.31 (+6.54%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CURX with… →

CURX Key Statistics

As of Sep 4, 2026
Trading
Open
$4.70
Previous Close
$4.74
Day's Range
4.64–5.40
52-Week Range
3.58–183.60
Volume
15.40K
Valuation
Market Cap
$7.92M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.86
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$4.23M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.57M
1-Year Return
−28.87%
Dividend and dates
Avg Volume
10.35K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CURX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1425.68%
2025 (partial year)−91.77%

As of September 4, 2026.

CURX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$4.23M
2024$0.00−$361.51K
2023$0.00−$19.20K
2022$26.00K−$20.23K−77.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00−$4.24M−$4.23M
2024$0.00−$290.39K−$361.51K
2023$0.00$0.00−$19.30K−$19.20K
2022$26.00K$4.43K−$20.23K−$20.23K−77.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CURX Valuation vs Biotechnology Median

Median of 656 stocks
MetricCURXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Curanex Pharmaceuticals Inc (CURX) carries a market capitalisation of $7.92M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 6.

CURX last closed at $5.05 on September 4, 2026. That is +$0.31 (+6.54%) against the previous close. The 52-week range on file runs from $3.58 to $183.60. The latest close sits 41.06% above that 52-week low.

Financial Health

In fiscal 2025, Curanex Pharmaceuticals Inc reported revenue of $0.00. The same year closed with a net loss of $4.23M. The reported profit margin is 0%. Trailing earnings per share are −7.86.

Across the 4 fiscal years on file, revenue moves from $26.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned −28.87%. Annualized volatility over the trailing 1 year is 1,854.49%.

Growth & Income

No dividend is on file for CURX.

2026 is still running; the price is +1,425.68% year to date.

Peer Comparison

Curanex Pharmaceuticals Inc (CURX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Curanex Pharmaceuticals Inc CURX $7.92M
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Curanex Pharmaceuticals Inc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

View all Biotechnology stocks →

Popular Healthcare Stocks

View all Healthcare stocks →

About Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.

Visit website →